AVIR Atea Pharmaceuticals Inc

USD 4.04 0.04 1
Icon

Atea Pharmaceuticals Inc (AVIR) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 4.04

+0.04 (+1.00)%

USD 0.34B

0.37M

N/A

USD 78.00 (+1830.69%)

Icon

AVIR

Atea Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 4.04
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.34B

USD 78.00 (+1830.69%)

USD 4.04

Atea Pharmaceuticals Inc (AVIR) Stock Forecast

N/A

Based on the Atea Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Atea Pharmaceuticals Inc is not available over the next 12 months. Atea Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Atea Pharmaceuticals Inc is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Atea Pharmaceuticals Inc’s stock price was USD 4.04. Atea Pharmaceuticals Inc’s stock price has changed by -1.46% over the past week, -7.55% over the past month and +29.49% over the last year.

No recent analyst target price found for Atea Pharmaceuticals Inc
No recent average analyst rating found for Atea Pharmaceuticals Inc

Company Overview Atea Pharmaceuticals Inc

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial...Read More

https://ateapharma.com

125 Summer Street, Boston, MA, United States, 02110

75

December

USD

USA

Adjusted Closing Price for Atea Pharmaceuticals Inc (AVIR)

Loading...

Unadjusted Closing Price for Atea Pharmaceuticals Inc (AVIR)

Loading...

Share Trading Volume for Atea Pharmaceuticals Inc Shares

Loading...

Compare Performance of Atea Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AVIR

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Atea Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing AVIR

Symbol Name AVIR's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Atea Pharmaceuticals Inc (AVIR) Stock

Stock Target Advisor's fundamental analysis for Atea Pharmaceuticals Inc's stock is Neutral.

Unfortunately we do not have enough data on AVIR's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on AVIR's stock to indicate what its average analyst target is.

AVIR stock's Price/Earning ratio is 9.85. Our analysis grades AVIR stock's Price / Earning ratio at F. This means that AVIR stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange. Based on this AVIR may be a overvalued for its sector.

The last closing price of AVIR's stock was USD 4.04.

The most recent market capitalization for AVIR is USD 0.34B.

Unfortunately we do not have enough analyst data on AVIR's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Atea Pharmaceuticals Inc's stock.

As per our most recent records Atea Pharmaceuticals Inc has 75 Employees.

Atea Pharmaceuticals Inc's registered address is 125 Summer Street, Boston, MA, United States, 02110. You can get more information about it from Atea Pharmaceuticals Inc's website at https://ateapharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...